• Browse
• Meine Registrierung (Login)
• Registrierung (frei)

Pharmaceutical News

• AARP Drug Price Survey Overlooks Critical Factors, Says Biotechnology Industry Organization
  Tue, 30 September 2008
  The following statement was issued today by the Biotechnology Industry Organization (BIO) regarding a new survey from the AARP on price trends for biotechnology drugs: The report issued yesterday by the AARP on price trends for specialty drugs ignores the many factors that counter and mitigate the price trends mentioned in ...
• Promising New TB Drug Receives Phase 2 SBIR
  Tue, 30 September 2008
  Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat infectious diseases of epidemic potential, has announced that it received a 2.
• Retrospective Analysis Of Phase 3 Data Suggest Wyeth's Investigational Compound Bazedoxifene
  Tue, 30 September 2008
  A retrospective analysis of Phase 3 two-year data presented at the annual meeting of the North American Menopause Society (NAMS) suggest that postmenopausal women treated with bazedoxifene/conjugated estrogens (BZA/CE) may experience incidence of breast tenderness and abnormal mammograms no greater than those treated with pl ...
• Potentia Pharmaceuticals Announces Positive Safety Data And Study Expansion In Phase I T ...
  Tue, 30 September 2008
  Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD) announced that the Company's leading drug candidate, POT-4, has shown early positive safety results in its Phase I study.
• Synvista Therapeutics Receives Approval To Begin Phase 2 Trial Of Topical SYI-2074 In Ps ...
  Tue, 30 September 2008
  Synvista Therapeutics, Inc. (Amex: SYI) announces that it has received approval from the Israeli Ministry of Health to begin a Phase 2 trial of a topical formulation of SYI-2074 in mild-to-moderate plaque psoriasis. The trial is expected to begin enrollment in the fourth quarter of 2008 at three sites ...
• Watson Announces Positive Data For RAPAFLO(TM)(silodosin), Its Investigational Product F ...
  Tue, 30 September 2008
  Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced that investigators presented efficacy and safety data on silodosin, its investigational treatment for benign prostatic hyperplasia (BPH, or prostate enlargement), at two regional meetings of the Ame ...
• ThromboGenics Announces Promising Results Of MITI IV Phase II Trial In The Treatment Of ...
  Tue, 30 September 2008
  ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, announces positive results from its MITI IV Phase II trial to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to acute s ...
• Run Out Of Pain Killers Again?
  Tue, 30 September 2008
  Research scientists at SINTEF have developed a control dashboard for the pharmaceuticals industry. This enables all pharmacies, wholesalers and manufacturers to check where products are in the supply chain, availability, what stocks the neighbouring pharmacy has and the future prognoses.
• VEGF Trap-Eye: New Data Confirm Successes In The Treatment Of Age Related Macular Degene ...
  Tue, 30 September 2008
  VEGF Trap-Eye can achieve durable improvements in visual acuity and in biologic measurement parameters in the formation of new blood vessels in the treatment of age-related macular degeneration (AMG). This was shown in the final evaluation of a Phase 2 study presented at the annual meeting of the Retina Society in Scottsdale ...
• Zypadhera(TM) Receives Positive Opinion From The European Committee For Medicinal Produc ...
  Tue, 30 September 2008
  The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Zypadhera (olanzapine powder and solvent for prolonged release suspension for injection, also known as olanzapine long-acting injection) for maintenance treatment of adult patients with schizophrenia sufficiently ...